Navigation Links
Genedata Phylosopher Selected for ERA-NET sncRNA Project
Date:6/1/2010

Genedata Phylosopher® is Central Management Solution for European Consortium Using Systems Biology to Study Infectious Diseases

(PRWEB) June 1, 2010 -- Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced it has been selected to participate in an ERA-Net-funded applied pathogenomics project, which is using systems biology to identify the role of small non-coding RNA (sncRNA) in infectious diseases. The sncRNAomics European Research Consortium is identifying novel targets for diagnostics and therapy of five major high-risk gram-positive human microbial pathogens. The Genedata Phylosopher biological data management solution was chosen as the central management and infrastructure platform for sharing and interpreting the experimental data, in particular the next-generation sequencing and tiling array data generated within the consortium.

“We chose to partner with Genedata because they have a successful track record in transcriptome-based biomarker identification and also because they have the strongest product portfolio for centralized data management for target validation,” explained Dr. Torsten Hain of the University of Giessen (Germany) and sncRNAomics Project Coordinator. “In health care, and especially in a clinical environment, microbial resistance increases exponentially. Antibiotics have become a blunt sword and we need new approaches in diagnostics and therapy,” continued Dr. Hain. “Small non-coding RNAs in bacteria are an emerging class of new gene expression regulators, but their role in colonization and pathogenicity is largely unknown. Within this interdisciplinary project we are applying for the first time a systems biology approach on major human pathogens to elucidate the role of sncRNAs, and to identify and validate new sncRNA-based diagnostic biomarkers and drug targets.”

Genedata Phylosopher will integrate all experimental data from the pathogens and the host organisms. Using a genome-wide scale and regulatory network approach, the consortium will adapt high-throughput technologies such as transcriptomics by tiling arrays as well as next-generation sequencing technologies to identify novel sncRNAs and to investigate their role in regulation. Genedata Phylosopher supports the reconstruction of disease pathways, in particular the refinement of functional assignment of genes, transcripts, proteins, regulatory motifs, RNAs and their molecular interactions, to regulatory networks during host-pathogen interactions.

"We are delighted to have this international and interdisciplinary consortium choose Genedata as their central data management and analysis infrastructure,” said Dr. Othmar Pfannes, CEO of Genedata. “This partnership further demonstrates Genedata’s leadership in delivering scalable and flexible research IT infrastructure solutions for target validation, drug development, and biomarker discovery, even for novel target classes such as sncRNAs.”

About sncRNAomics European Research Consortium
Novel anti-infectives are of high priority for global health care and sncRNAs in bacteria are an emerging class of new gene expression regulators, but their role in colonization and pathogenicity in largely unknown. The consortium brings together seven research groups from three countries to combine novel high-throughput sncRNA screening methods, whole-genome transcriptomics and proteomics and bioinformatics. These methods will be coupled with molecular characterization to provide new data regarding sncRNAs in major high-risk Grampositive microbes (e.g. Staphylococcus, Streptococcus, Enterococcus, Clostridium, and Listeria). Potential new drugs and diagnostic biomarkers will be validated using tissue culture and subsequently in in-vivo models. The sncRNAomics project is granted under the frame of the second multinational ERA-Net PathoGenoMics call. For more information, please visit www.pathogenomics-era.net/2ndJointCall.

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead and biomarker discovery. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata Phylosopher®, Genedata Screener®, Genedata Expressionist®, and Genedata Analyst™ make research data accessible and understandable, enabling scientific discovery that fights disease and improves health worldwide. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Japan, Germany and the US. www.genedata.com.

###

Read the full story at http://www.prweb.com/releases/2010/06/prweb4072014.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. Genedata Expressionist 6 with New Refiner MS Capabilities Debuts at 58th ASMS Conference on Mass Spectrometry
2. German MedSys Project Adopts Genedata Phylosopher for Research Informatics
3. Genedata Screener 8 Advancing Analysis of HCS, HTS and Time Series Data Debuts at SBS 16th Annual Conference
4. Genedata Announces Five-Year Agreement Extension with Kluyver Centre for Genomics of Industrial Fermentation
5. Bringing Statistics to Biologists - New Genedata Analyst Launches at Society of Toxicology 49th Annual Meeting
6. Evonik Extends Long-term Research & Development Partnership with Genedata
7. RIKEN Center for Genomics Medicine Chooses Genedata Expressionist for High Throughput Proteomics R&D
8. Genedata at HCA Announces Banner Year for Genedata Screener at Leading Pharmaceutical Companies
9. MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products
10. Genedata and the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project
11. Genedata Screener Supports Small Molecule Research at the Broad Institute of Harvard and MIT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... , ... August 16, 2017 , ... ... microbe delivery system, announced it has secured $2M in funding from an impressive ... Angels, Carmen Innovations, and SVG Thrive Fund. With this investment, 3Bar is broadening ...
(Date:8/16/2017)... WAKEFIELD, Mass. , Aug. 16, 2017  This year,s edition of ... global leader in life sciences workforce solutions, has made the list for ... Inc. 5000 recognizes the nation,s fastest-growing private companies based on a set ... Fast 50, which includes the fastest-growing companies in the Bay ... Inc. 5000 ...
(Date:8/15/2017)... , Aug. 15, 2017 After spending the past two ... with crowdsourced data collection, GeneFo now offers this platform to healthcare ... and amplifying support, adherence, and data collection vis a vis their ... mark the successful launch of this offer. ... GeneFo ...
(Date:8/15/2017)... Diego, CA (PRWEB) , ... August 15, 2017 ... ... company pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch ... the number of steps needed to gain kinetic binding data for a wide ...
Breaking Biology Technology:
(Date:6/30/2017)... 30, 2017 Today, American Trucking Associations ... of face and eye tracking software, became the ... program. "Artificial intelligence and advanced ... monitor a driver,s attentiveness levels while on the ... to detect fatigue and prevent potential accidents, which ...
(Date:5/23/2017)... Italy , May 23, 2017  Hunova, the first robotic gym ... trunk, has been officially launched in Genoa, Italy . ... Europe and the USA . The technology ... on the market by the IIT spin-off Movendo Technology thanks to a ... the Multimedia News Release, please click: ...
(Date:5/6/2017)... 2017 RAM Group , Singaporean ... breakthrough in biometric authentication based on a ... to perform biometric authentication. These new sensors are based ... by Ram Group and its partners. This sensor will ... chains and security. Ram Group is a next ...
Breaking Biology News(10 mins):